流体限制用于治疗早产婴儿有症状的动脉管在早产婴儿
Abigale MacLellan1, Austin J Cameron-Nola2, Chris Cooper3
1Faculty of Medicine, Dalhousie University, Halifax, Canada.
The Cochrane database of systematic reviews
|December 18, 2024
概括
没有发现随机对照试验 (RCT) 来评估在早产婴儿中症状性专动脉管 (PDA) 的液体限制. 需要进一步的RCT来确定PDA治疗中液体限制的益处和危害.
科学领域:
- 新生儿医学 新生儿医学
- 儿童心脏病学 儿童心脏病学
- 基于证据的医学基于证据的医学.
背景情况:
- 专利性动脉管 (PDA) 是早产婴儿常见的疾病,可能导致严重的并发症.
- 液体限制是对症状PDA的建议管理策略,但其对极度早产婴儿的影响尚不清楚.
- 系统地评估液体限制在治疗症状性PDA中的有效性和安全性,对于临床决策至关重要.
研究的目的:
- 评估液体限制对早产婴儿患有PDA症状的发病率和死亡率的影响.
- 系统地审查现有关于症状PDA治疗流体限制的证据.
主要方法:
- 搜索了多个数据库 (CENTRAL,MEDLINE,Embase) 和临床试验注册到2023年10月.
- 计划包括随机对照试验 (RCT),涉及患有PDA症状的早产新生儿.
- 主要结局是PDA关闭;次要结局包括死亡率,干预和其他疾病.
主要成果:
- 没有确定符合纳入标准的已完成或正在进行的RCT.
- 关于早产婴儿症状性PDA的液体限制的有效性和安全性的RCT缺乏证据.
结论:
- 目前,没有RCT证据指导在早产婴儿症状PDA的液体限制的使用.
- 需要高质量的RCT来确定这种脆弱人群中流体限制的益处和危害.
相关概念视频
01:25Mitral Regurgitation III: Medical Management
1
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
1
01:28Mitral Regurgitation IV: Nursing Management
1
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
1